- Home
- OMER vs GWRS Comparison
OMER vs GWRS Comparison
Compare OMER & GWRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- GWRS
- Stock Information
- Founded
- OMER 1994
- GWRS 2003
- Country
- OMER United States
- GWRS United States
- Employees
- OMER N/A
- GWRS N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- GWRS Water Supply
- Sector
- OMER Health Care
- GWRS Utilities
- Exchange
- OMER Nasdaq
- GWRS Nasdaq
- Market Cap
- OMER 274.3M
- GWRS 265.4M
- IPO Year
- OMER 2009
- GWRS 2010
- Fundamental
- Price
- OMER $4.48
- GWRS $10.85
- Analyst Decision
- OMER Strong Buy
- GWRS
- Analyst Count
- OMER 5
- GWRS 0
- Target Price
- OMER $18.00
- GWRS N/A
- AVG Volume (30 Days)
- OMER 933.6K
- GWRS 63.4K
- Earning Date
- OMER 11-12-2025
- GWRS 11-05-2025
- Dividend Yield
- OMER N/A
- GWRS 2.83%
- EPS Growth
- OMER N/A
- GWRS N/A
- EPS
- OMER N/A
- GWRS 0.22
- Revenue
- OMER N/A
- GWRS $54,270,000.00
- Revenue This Year
- OMER N/A
- GWRS $8.22
- Revenue Next Year
- OMER N/A
- GWRS $8.43
- P/E Ratio
- OMER N/A
- GWRS $49.31
- Revenue Growth
- OMER N/A
- GWRS 4.33
- 52 Week Low
- OMER $2.95
- GWRS $9.27
- 52 Week High
- OMER $13.60
- GWRS $13.98
- Technical
- Relative Strength Index (RSI)
- OMER 56.41
- GWRS 70.10
- Support Level
- OMER $4.07
- GWRS $9.98
- Resistance Level
- OMER $4.72
- GWRS $10.33
- Average True Range (ATR)
- OMER 0.23
- GWRS 0.26
- MACD
- OMER 0.02
- GWRS 0.06
- Stochastic Oscillator
- OMER 61.19
- GWRS 84.49
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.